Rajni Agarwal-Hashmi, MD, on Safety Advantages of Gene Therapy in Fanconi Anemia Over SOC
The professor of pediatrics at Stanford Cancer Institute discussed recent data from clinical trials of the lentiviral gene therapy RP-L102.
Diane Simeone, MD, on Screening Patients for CAR-T Eligibility Before Solid Tumor Relapse
Simeone discussed the progress and challenges seen so far in the BASECAMP-1 observational study.
Adam Cuker, MD, on Higher Efficacy of Gene Therapy Over SOC in Hemophilia B
The associate professor of medicine at University of Pennsylvania discussed new data from the BENEGENE-2 study of fidanacogene elaparvovec.
Diane Simeone, MD, on Addressing Unmet Needs in Colorectal Cancer, NSCLC, and Pancreatic Cancer
Simeone discussed the design of BASECAMP-1, an observational study for patients previously treated for solid tumors who are at a high risk of relapse.
Etranacogene Dezaparvovec “Transformative” for Patients With Hemophilia B
Steven Pipe, MD, CS Mott Children’s Hospital, discussed the latest follow-up data from the HOPE-B study of the approved therapy, Hemgenix.
Alan Trounson, PhD, MSc, on New Frontiers in Allogeneic Cell Therapy
The chief executive officer of Cartherics discussed the company’s development of NK cell, T-cell, and macrophage cell therapies for various solid tumor indications.
Akshay Sharma, MBBS, on Investigating CRISPR/Cas9 Edited Cells for Sickle Cell Disease
The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed advantages of OTQ923 in treating SCD.
Arshad Khanani, MD, on Restoring Aflibercept Expression in Wet AMD With Gene Therapy
The director of clinical research at Sierra Eye Associates discussed data from the phase 1/2 PRISM study.
Terese Hammond, MD, on Promising Data With iNKT Cells in COVID-associated ARDS
The director of the CCU/ICU at Saint John’s Health Center discussed updated data from a phase 1/2 trial of agenT-797.
Armin Ghobadi, MD, on Assessing CAR-T Cell Combination Therapies
The associate professor of medicine at Siteman Cancer Center and WUSTL discussed further research to be done with CAR T-cell therapies.
Ivan Horak, MD, on Early Clinical Efficacy of Allogeneic CD30.CAR EBVST Cell Therapy in Lymphomas
The chief medical and scientific officer of Tessa Therapeutics discussed data from the BESTA and CHARIOT studies presented at ASH 2022.
Giedre Krenciute, PhD, on Revitalizing T-cells in CAR T-cell Therapy
The assistant member of the bone marrow transplantation and cellular therapy department at St. Jude Children’s Hospital discussed preclinical research presented at ASH 2022.
Rebecca Epperly, MD, on Emerging Clinical Research With Cell Therapy in Leukemia, Lymphoma
The clinician scientist at St. Jude Children’s Research Hospital discussed the session on cell therapies in acute leukemias and Hodgkin lymphoma she moderated at ASH 2022.
Paulina Velasquez, MD, on Finding New Targets for Cell Therapy
The assistant member at St. Jude Children’s Research Hospital discussed the ASH 2022 basic and translational science session she moderated.
Developing Nonviral Gene Therapy for Hemophilia A
Brent Warner, president, gene therapy, Poseida Therapeutics, discussed data on the preclinical P-FVIII-101 presented at ASH 2022.
Cilta-cel Garners More Positive Data in Early and Late Relapsed Multiple Myeloma Treatment
Ying Huang, chief executive officer, Legend Biotech, discussed new data from the CARTIFAN-1 and CARTITUDE-2 studies.
Jakub Svoboda, MD, on Promising Efficacy With huCART19-IL18 in NHL, CHL
The associate professor of medicine from University of Pennsylvania discussed updated data on huCART19-IL18 presented at the ASH 2022 meeting.
Swati Naik, MBBS, on Investigating CD123-CAR T Therapy for Relapsed AML
The assistant member at St. Jude Children’s Research Hospital discussed updated data from a phase 1 study being conducted at the hospital.
Armin Ghobadi, MD, on Helping Expand CAR T Cells With NT-I7
The associate professor of medicine at Siteman Cancer Center and WUSTL discussed updated data from a study of NT-I7 and tisa-cel presented at ASH 2022.
Steven Pipe, MD, on Continuing Durability of Etranacogene Dezaparvovec in Hemophilia B
The professor of pediatric hematology/oncology at CS Mott Children’s Hospital discussed new follow-up data from the HOPE-B study presented at ASH 2022.
Sham Mailankody, MBBS, on Updates on ALLO-715 CAR T in R/R Multiple Myeloma
The associate attending physician at Memorial Sloan Kettering Cancer Center discussed updated data presented at the ASH 2022 meeting.
David Sallman, MD, on Advantages of Allogeneic CAR T-Cell Therapy in AML
The assistant member of the department of malignant hematology at Moffitt Cancer Center discussed unmet needs in acute myeloid leukemia and how UCART123v1.2 may address these.
Akshay Sharma, MBBS, on Inducing Fetal Hemoglobin in Sickle Cell With CRISPR/Cas9-Edited Stem Cells
The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed new data from a phase 1/2 trial presented at ASH 2022.
Gerhard Ehninger, MD, on Beneficial Safety in AML With Rapidly Switchable CAR Therapy
The professor at University Hospital Dresden discussed data presented at the 2022 ASH meeting.
Matthew Frigault, MD, MS, on CART-ddBCMA's Potential in Multiple Myeloma
The study's primary investigator shared his thoughts on where CART-ddBCMA could fit within the treatment landscape.
Aimee C. Talleur, MD, on Predicting Response and Toxicity to Cell Therapy
The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed the session she moderated at the ASH 2022 annual meeting.
Nirav N. Shah, MD, on Unmet Needs With CAR T-Cell Therapies in Hematologic Malignancies
The associate professor from the Medical College of Wisconsin discussed how to address unmet needs with CAR T-cell therapies.
Maria Escolar, MD, on Combining HSCT With Gene Therapy in Krabbe Disease
The chief medical officer of Forge Biologics discussed the potential advantages of the investigational combination therapy approach.
Maria Escolar, MD, on Addressing Unmet Needs in Krabbe Disease With Gene Therapy
The chief medical officer of Forge Biologics discussed clinical data presented at ESGCT.
Shebli Atrash, MD, on BCMA-Directed Therapy Options for Multiple Myeloma
Shebli Atrash, MD, discussed the current landscape of available BCMA-directed therapies for treating multiple myeloma.
